Anil K. Sood, MD: The Phase III Study Of Pazopanib for Ovarian Cancer

Dr. Anil Sood sits down with Selma Schimmel on The Group Room where they discuss the phase III study of pazopanib as well as touch on a cervical cancer study citing use of an Anti-angiogenesis drug does provide benefit for patients with cervical cancer.

This interview was filmed at the American Society of Clinical Oncology Annual Meeting in Chicago 2013.

Anil K. Sood, MD:  Graduate Faculty, Regular Member, Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX

Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Director, Ovarian Cancer Research, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Vice Chairman, Department of Gynecologic Oncology and Reproductive Medicine, Translational Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Director, Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX

Director, Blanton-Davis Ovarian Cancer Research Program, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Advocacy and educational support provided at ASCO 2013, in part, by:

TGR ASCO 2013 Sponsor

 

Comments